ECTRIMS 2023

Machine learning to identify cognitive phenotypes in MS 3:13
Machine learning to identify cognitive phenotypes in MS
Elisa Colato • 11 Oct 2023
Metabolic pathways in CNS inflammation: how valine catabolism modulates autoimmune inflammation 4:12
Metabolic pathways in CNS inflammation: how valine catabolism modulates autoimmune inflammation
André Ortlieb Guerreiro Cacais • 23 Oct 2023
iPSC-based tool for CNS antibody detection in multiple sclerosis 2:31
iPSC-based tool for CNS antibody detection in multiple sclerosis
Amandine Mathias • 3 Oct 2023
Evolution of understanding and treatment in NMOSD 6:10
Evolution of understanding and treatment in NMOSD
Brian Weinshenker • 23 Oct 2023
The potential role of BTK inhibitors in addressing MS treatment gaps 1:40
The potential role of BTK inhibitors in addressing MS treatment gaps
Erik Wallstroem et al. • 12 Oct 2023
Navigating the treatment landscape in MS: the potential of BTK inhibitors 3:31
Navigating the treatment landscape in MS: the potential of BTK inhibitors
Erik Wallstroem et al. • 12 Oct 2023
Influence of metabolites on inflammation and dietary implications 2:38
Influence of metabolites on inflammation and dietary implications
André Ortlieb Guerreiro Cacais • 23 Oct 2023
Detection of CNS-reactive antibodies using iPSC-derived antigen based platform 3:39
Detection of CNS-reactive antibodies using iPSC-derived antigen based platform
Amandine Mathias • 3 Oct 2023
The potential of machine learning in clinical decision-making 0:44
The potential of machine learning in clinical decision-making
Elisa Colato • 11 Oct 2023
Distinctive attributes and efficacy of inebilizumab in NMOSD 8:16
Distinctive attributes and efficacy of inebilizumab in NMOSD
Brian Weinshenker • 23 Oct 2023
Baseline characteristics in the HERCULES trial: tolebrutinib in non-relapsing SPMS 2:28
Baseline characteristics in the HERCULES trial: tolebrutinib in non-relapsing SPMS
Erik Wallstroem et al. • 12 Oct 2023
Unlocking clinical potential: autoantibody detection and antigen discovery 2:04
Unlocking clinical potential: autoantibody detection and antigen discovery
Amandine Mathias • 3 Oct 2023
Prospects and challenges in NMOSD treatment 3:04
Prospects and challenges in NMOSD treatment
Brian Weinshenker • 23 Oct 2023
The next steps for tolebrutinib in MS 1:44
The next steps for tolebrutinib in MS
Erik Wallstroem et al. • 12 Oct 2023
NEXT-MS trial: natalizumab personalized extended interval dosing 3:26
NEXT-MS trial: natalizumab personalized extended interval dosing
Alyssa Toorop • 19 Oct 2023
Decoding the genetic predisposition to PML in patients on natalizumab 4:26
Decoding the genetic predisposition to PML in patients on natalizumab
Eli Hatchwell • 24 Oct 2023
The content of VJNeurology is intended for healthcare professionals